Previous 10 | Next 10 |
Live moderated video webcast on Wednesday, July 12 th at 10:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / July 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard ...
2023-05-16 11:27:04 ET Cell therapy company Xenetic Biosciences ( NASDAQ: XBIO ) trended lower Tuesday after H.C. Wainwright downgraded its shares to Neutral from Buy, citing concerns on the biotech’s catalysts path. Despite the company’s recently-announced rever...
2023-05-12 13:03:39 ET Xenetic Biosciences ( NASDAQ: XBIO ) has announced it will effect a one-for-ten reverse stock split of its outstanding common stock, effective May 15, 2023. The company expects that upon the opening of trading on May 15, 2023, its common stock will ...
- Continued progress with the DNase-based oncology program towards Phase 1 study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors - Ended the quarter with $12.0 million of cash to fund operations and drive pipeline forward FRAMINGHAM, MA / A...
Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertise FRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharm...
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planning FRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceu...
- Collaboration provides a significant step forward in the advancement of Xenetic's DNase-based oncology program towards Phase 1 clinical development - Systemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinoma FRAMINGHAM, MA / ACCESSWIRE /...
- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Phase 1 clinical development - Closed the year with $13.1 million of cash expected to fun...
Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29 th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / March 16, 2023 / Xenetic Biosciences, Inc. (NASDAQ:X...
Xenetic Biosciences ( NASDAQ: XBIO ) stock rose ~14% on Tuesday after the company said that the Canadian Intellectual Property Office (CIPO) issued a notice of allowance for a patent covering use of DNase enzyme for preventing or improving toxicity associated with chemotherapy. ...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...
- Company building growing body of preclinical data to guide pathway to first in human trial for DNase-based oncology platform FRAMINGHAM, MA / ACCESSWIRE / January 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advan...
Encouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platform Driving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Continuing partnering discus...